Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Bayshore Community Hospital — Holmdel, New Jersey
- Monmouth Medical Center Southern Campus — Lakewood, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in New Jersey: - Virtua Samson Cancer Center — Moorestown, New Jersey
- Virtua Voorhees — Voorhees Township, New Jersey
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in New Jersey: - Local Institution - 007-993 — Belleville, New Jersey
- Astera Cancer Care - East Brunswick — East Brunswick, New Jersey
- John Theurer Cancer Center — Hackensack, New Jersey
- Local Institution - 007-975-A — Somerset, New Jersey
- Local Institution - 007-975-B — Somerset, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in New Jersey: - Essex Oncology of North Jersey — Belleville, New Jersey
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in New Jersey: - Clinical Study Site — Mullica Hill, New Jersey
- Clinical Study Site — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in New Jersey: - Jefferson Health - Cherry Hill — Cherry Hill, New Jersey
- Sidney Kimmel Cancer Center - Washington Township — Sewell, New Jersey
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in New Jersey: - Astera Cancer Care - 1128 — East Brunswick, New Jersey
Phase 3 Recruiting Industry
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…
Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in New Jersey: - Research Site — East Brunswick, New Jersey
- Research Site — Florham Park, New Jersey
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in New Jersey: - Meridian Health System — Neptune City, New Jersey
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in New Jersey: - Astera Cancer Care — East Brunswick, New Jersey
- Summit Medical Group PA — Florham Park, New Jersey
- The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion — Paramus, New Jersey
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in New Jersey: - Atlantic Health System Morristown Medical Center ( Site 0121) — Morristown, New Jersey
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in New Jersey: - Virtua Samson Cancer Center — Moorestown, New Jersey
- Virtua Voorhees — Voorhees Township, New Jersey
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in New Jersey: - Hunterdon Hematology Oncology — Flemington, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Overlook Medical Center — Summit, New Jersey
- Holy Name Medical Center — Teaneck, New Jersey
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in New Jersey: - MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; th…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT06667908
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting Industry
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06465329
Sites in New Jersey: - Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting Industry
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + …
Sponsor: Genelux Corporation
NCT ID: NCT06463665
Sites in New Jersey: - Inspira Medical Center Mullica Hill — Mullica Hill, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Jersey: - Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
- Summit Medical Group (site 205) — Florham Park, New Jersey
- Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other
Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carbop…
Sponsor: PrECOG, LLC.
NCT ID: NCT07057791
Sites in New Jersey: - Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey: - John Theurer Cancer Center — Hackensack, New Jersey
Phase 2 Recruiting Industry
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monot…
Sponsor: Genmab
NCT ID: NCT07288177
Sites in New Jersey: - Astera Cancer Care — East Brunswick, New Jersey
Phase 2 Recruiting Industry
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a per…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07221474
Sites in New Jersey: - Valley Health Systems - Ridgewood Campus ( Site 0010) — Paramus, New Jersey